Skip to navigation Skip to content

T-cell lymphoma Program in Pharmaceutical Benefits Scheme (PBS) 012-18051112

Expand/Collapse all sectionsExpand all



T-cell Lymphoma restriction and item codes

Do not share this attachment externally. See Freedom of Information - Information Publication Scheme.

https://ourblueprint.internal.dept.local/content/images/icon-hidden-attachment.png|A linked attachment is available for staff only (i.e. under IPS/FOI)PBS CTCL and PTCL restriction and item codes

Contact details

Complex Drugs Programs

Forms

Cutaneous T-cell lymphoma - mogamulizumab or vorinostat - initial authority application (PB216)

Cutaneous T-cell lymphoma - brentuximab vedotin - initial authority application (PB268)

Peripheral T-cell lymphoma - brentuximab vedotin - initial authority application (PB314)

Services Australia website

T-cell lymphoma

External website

PBS schedule for T-cell lymphoma

FAQs from Service Officers

Table 1: see Table 2 in Processing Complex Authority Required Listings for FAQs about all Complex programs.

Item

Description

1

How is the quantity of brentuximab and mogamulizumab entered in OPA?

The quantity must be entered in OPA as the required dose in milligrams (mg). See Recording dose and frequency in online pbs authorities system for more details.

2

If a dose change for brentuximab or mogamulizumab is required, does the prescriber need to obtain a new approval?

Yes. Any dose change of greater than 10%, whether an increase or a decrease, requires a new approval. Any replacement for a dose change must be entered under the same item and restriction code as the previous approval, and the relevant rejection should be overridden with the comment 'dose change'.